Abstract
Worldwide, tuberculosis is the leading cause of morbidity and mortality due to a single bacterial pathogen, Mycobacterium tuberculosis (Mtb). The increasing prevalence of this disease, the emergence of multi-, extensively, and totally drug-resistant strains, complicated by co-infection with the human immunodeficiency virus, and the length of tuberculosis chemotherapy have led to an urgent and continued need for the development of new and more effective antitubercular drugs. Within this context, the L-histidine biosynthetic pathway, which converts 5-phosphoribosyl 1-pyrophosphate to L-histidine in ten enzymatic steps, has been reported as a promising target of antimicrobial agents. This pathway is found in bacteria, archaebacteria, lower eukaryotes, and plants but is absent in mammals, making these enzymes highly attractive targets for the drug design of new antimycobacterial compounds with selective toxicity. Moreover, the biosynthesis of L-histidine has been described as essential for Mtb growth in vitro. Accordingly, a comprehensive overview of Mycobacterium tuberculosis histidine pathway enzymes as attractive targets for the development of new antimycobacterial agents is provided, mainly summarizing the previously reported inhibition data for Mtb or orthologous proteins.
Keywords: Drug design, enzymatic inhibitors, antimycobacterial, L-histidine biosynthesis, molecular target, Mycobacterium tuberculosis.
Current Topics in Medicinal Chemistry
Title:Targeting the Histidine Pathway in Mycobacterium tuberculosis
Volume: 13 Issue: 22
Author(s): Juleane Lunardi, José Eduardo S. Nunes, Cristiano V. Bizarro, Luiz Augusto Basso, Diógenes Santiago Santos and Pablo Machado
Affiliation:
Keywords: Drug design, enzymatic inhibitors, antimycobacterial, L-histidine biosynthesis, molecular target, Mycobacterium tuberculosis.
Abstract: Worldwide, tuberculosis is the leading cause of morbidity and mortality due to a single bacterial pathogen, Mycobacterium tuberculosis (Mtb). The increasing prevalence of this disease, the emergence of multi-, extensively, and totally drug-resistant strains, complicated by co-infection with the human immunodeficiency virus, and the length of tuberculosis chemotherapy have led to an urgent and continued need for the development of new and more effective antitubercular drugs. Within this context, the L-histidine biosynthetic pathway, which converts 5-phosphoribosyl 1-pyrophosphate to L-histidine in ten enzymatic steps, has been reported as a promising target of antimicrobial agents. This pathway is found in bacteria, archaebacteria, lower eukaryotes, and plants but is absent in mammals, making these enzymes highly attractive targets for the drug design of new antimycobacterial compounds with selective toxicity. Moreover, the biosynthesis of L-histidine has been described as essential for Mtb growth in vitro. Accordingly, a comprehensive overview of Mycobacterium tuberculosis histidine pathway enzymes as attractive targets for the development of new antimycobacterial agents is provided, mainly summarizing the previously reported inhibition data for Mtb or orthologous proteins.
Export Options
About this article
Cite this article as:
Lunardi Juleane, Nunes Eduardo S. José, Bizarro V. Cristiano, Basso Augusto Luiz, Santos Santiago Diógenes and Machado Pablo, Targeting the Histidine Pathway in Mycobacterium tuberculosis, Current Topics in Medicinal Chemistry 2013; 13 (22) . https://dx.doi.org/10.2174/15680266113136660203
DOI https://dx.doi.org/10.2174/15680266113136660203 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Application of dsRNA in Cancer Immunotherapy: Current Status and Future Trends
Anti-Cancer Agents in Medicinal Chemistry Virus Diagnostics on Microarrays
Current Pharmaceutical Biotechnology Recent Developments in Oral Bait Vaccines for Wildlife
Recent Patents on Drug Delivery & Formulation The First Approved Agent in the Glitazar’s Class: Saroglitazar
Current Drug Targets Modulation of Inflammatory Immune Reactions by Low-Dose Ionizing Radiation: Molecular Mechanisms and Clinical Application
Current Medicinal Chemistry Closing the Gap: An Atomistic Structural and Functional Perspective of S. <i>mansoni</i> Universal Stress G4LZI3 Protein in Complex with Phenolic Compounds
Current Drug Discovery Technologies G-Protein Coupled Receptors (GPCRs): A Comprehensive Computational Perspective
Combinatorial Chemistry & High Throughput Screening α-Galactosylceramide: Potential Immunomodulatory Activity and Future Application [General Articles]
Current Medicinal Chemistry MDR/XDRTB: What are the New Treatment Options?
Current Respiratory Medicine Reviews Importance of Amino Acids, Gln-119 and Tyr-376, in the S1 Pocket of Escherichia coli Peptidase N in Determining Substrate Specificity
Protein & Peptide Letters A Bibliometric Analysis of Global Research on Lophomonas Spp. in Scopus (1933-2019)
Infectious Disorders - Drug Targets The Co-agonist Site of NMDA-glutamate Receptors: A Novel Therapeutic Target for Age-related Cognitive Decline
Current Pharmaceutical Design A Novel Method for Preparation of Linezolid, (S)-N-((3-(3-Fluoro-4- Morpholinophenyl)-2-Oxo-5-Oxazolidinyl) Methyl) Acetamide
Letters in Organic Chemistry The Indian Pediatric HIV Epidemic: A Systematic Review
Current HIV Research Patent Selections:
Recent Patents on Anti-Infective Drug Discovery Strategies for Effective Naked-DNA Vaccination Against Infectious Diseases
Recent Patents on Anti-Infective Drug Discovery B-Cell Based Gene Therapy for Autoimmune Diseases
Infectious Disorders - Drug Targets Ligand-Receptor Communication and Drug Design
Current Protein & Peptide Science Update on Anti-TNF-Alpha Treatment in Rheumatic Diseases
Current Drug Therapy Antimicrobial peptides for the treatment of pulmonary tuberculosis, allies or foes?
Current Pharmaceutical Design